Breeze Holdings Acquisition Corp.'s shareholders approve the business combination with YD Biopharma Limited.
The combined company, to be named YD Bio Limited, is set to trade on Nasdaq under ticker symbol YDES.
The transaction is expected to close in the coming days, pending customary closing conditions.
Shareholder Approval
Stockholders voted in favor of the Business Combination Proposal with a significant majority.
New Ticker Symbol
The combined company will be listed on Nasdaq under the ticker symbol YDES.
Advisors
Legal advisor to YD Biopharma is ArentFox Schiff LLP and financial advisor to Breeze is I-Bankers Securities, Inc.
- YD Biopharma Limited's focus on developing vaccines and therapeutic biologics for infectious diseases aligns with Breeze's strategic goals.
- The approval of the Business Combination Proposal sets the stage for YD Biopharma's expansion into the public market.
The successful approval of the business combination marks a significant milestone for YD Biopharma Limited, paving the way for enhanced growth opportunities and market visibility.